{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:55:38Z","timestamp":1791532538365,"version":"4.3.4"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Cocaine use disorder is a serious public health problem and no medications have been proven effective for its treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate psilocybin in the treatment of cocaine use disorder. It was hypothesized that psilocybin, compared with placebo, would yield a higher percentage of cocaine abstinent days, a greater likelihood of complete abstinence from cocaine, and a greater latency to first cocaine lapse through 180 days after end of treatment.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Randomized, quadruple-blind, placebo-controlled clinical trial at a major medical research center in the Deep South of the US. Participants were individuals with cocaine use disorder who were motivated to quit and without significant comorbidities, recruited between May 2015 and August 2023 with data collection completed in May 2024.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized (1:1) to receive a single oral dose of psilocybin (25 mg per 70 kg of body weight) or active placebo (100 mg diphenhydramine). All participants received manualized psychotherapy that incorporated cognitive-behavioral treatment approximately 1 month before and 1 month after an all-day investigational drug treatment session.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Percentage of cocaine abstinent days, rates of complete cocaine abstinence, and time to first cocaine lapse through 180 days after end of treatment, assessed by timeline followback interview and confirmed with urinalysis. Hypotheses were formulated before data collection and analyses followed intention-to-treat principles.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 40 participants, 33 (82.5%) were men, the median (IQR) age was 50.0 (43.8-56.0) years, 33 (82.5%) were Black, and 7 (17.5%) were White. Most participants had lower socioeconomic status, with 26 participants (65%) having an annual income of $20\u202f000 or less. Four participants were lost to follow-up, resulting in 36 participants who completed assessments through 180 days after end of treatment. Psilocybin recipients had a higher percentage of cocaine abstinent days (\u03b2\u2009=\u200928.95; 95% CI, 18.22-39.67;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), greater likelihood of complete cocaine abstinence (odds ratio, 18.37; 95% CI, 1.92-2468.17;\n P<\/jats:italic>\n \u2009=\u2009.007), and a reduced risk of cocaine lapse over time (hazard ratio, 0.28; 95% CI, 0.13-0.60;\n P<\/jats:italic>\n \u2009=\u2009.001) than active placebo recipients. No serious adverse events occurred.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, psilocybin appeared to be safe and efficacious for treating cocaine use disorder among individuals from underrepresented and vulnerable populations. Further research is warranted to replicate and expand these findings.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02037126<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.11029","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:30:22Z","timestamp":1778167822000},"page":"e2611029","source":"Crossref","is-referenced-by-count":10,"title":["Psilocybin in the Treatment of Cocaine Use Disorder"],"prefix":"10.1001","volume":"9","author":[{"given":"Peter S.","family":"Hendricks","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara N.","family":"Lappan","sequence":"additional","affiliation":[{"name":"Department of Health Behavior, University of Alabama at Birmingham School of Public Health, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Shelton","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne C.","family":"Lahti","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Cropsey","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Bradley","sequence":"additional","affiliation":[{"name":"Department of Health Behavior, University of Alabama at Birmingham School of Public Health, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Simonsson","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori L.","family":"Davis","sequence":"additional","affiliation":[{"name":"Birmingham VA Health Care System, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Grossman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia E.","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"1-2","key":"zoi260336r2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.drugalcdep.2010.11.004","article-title":"Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).","volume":"115","author":"Lopez-Quintero","year":"2011","journal-title":"Drug Alcohol Depend"},{"issue":"549","key":"zoi260336r3","article-title":"Drug overdose deaths in the United States, 2023-2024.","author":"Garnett","year":"2026","journal-title":"NCHS Data Brief"},{"issue":"6","key":"zoi260336r4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"zoi260336r5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266142","article-title":"Relative effectiveness of medications for opioid-related disorders: a systematic review and network meta-analysis of randomized controlled trials.","volume":"17","author":"Lim","year":"2022","journal-title":"PLoS One"},{"key":"zoi260336r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107454","article-title":"Efficacy of medications for the treatment of alcohol use disorder (AUD): a systematic review and meta-analysis considering baseline AUD severity.","volume":"209","author":"Agabio","year":"2024","journal-title":"Pharmacol Res"},{"issue":"6","key":"zoi260336r7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2022.0395","article-title":"Treatment of tobacco smoking: a review.","volume":"327","author":"Rigotti","year":"2022","journal-title":"JAMA"},{"issue":"10","key":"zoi260336r8","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1111\/add.16529","article-title":"Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial.","volume":"119","author":"Li","year":"2024","journal-title":"Addiction"},{"issue":"12","key":"zoi260336r9","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1007\/s11606-019-05074-8","article-title":"Pharmacotherapy for cocaine use disorder\u2014a systematic review and meta-analysis.","volume":"34","author":"Chan","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"9","key":"zoi260336r10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/j.1360-0443.2009.02879.x","article-title":"Contingency management treatments: controversies and challenges.","volume":"105","author":"Petry","year":"2010","journal-title":"Addiction"},{"issue":"5","key":"zoi260336r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8049","article-title":"Comparison of treatments for cocaine use disorder among adults: a systematic review and meta-analysis.","volume":"4","author":"Bentzley","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi260336r12","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1176\/appi.ajp.20250053","article-title":"Contingency management for stimulant use disorder and association with mortality: a cohort study.","volume":"182","author":"Coughlin","year":"2025","journal-title":"Am J Psychiatry"},{"issue":"18","key":"zoi260336r13","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi260336r14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial.","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"zoi260336r15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial.","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"12","key":"zoi260336r16","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"zoi260336r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"7","key":"zoi260336r18","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"6","key":"zoi260336r19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study.","volume":"28","author":"Savage","year":"1973","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"zoi260336r20","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial.","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"zoi260336r21","doi-asserted-by":"publisher","DOI":"10.1111\/add.70152","article-title":"Psilocybin in alcohol use disorder and comorbid depressive symptoms: results from a feasibility randomized clinical trial.","author":"Luquiens","year":"2025","journal-title":"Addiction"},{"key":"zoi260336r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103149","article-title":"Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial.","volume":"82","author":"Rieser","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"3","key":"zoi260336r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.0972","article-title":"Psilocybin or nicotine patch for smoking cessation: a pilot randomized clinical trial.","volume":"9","author":"Johnson","year":"2026","journal-title":"JAMA Netw Open"},{"key":"zoi260336r24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081123","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials.","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"issue":"4","key":"zoi260336r25","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1037\/0022-006X.59.4.526","article-title":"Effects of commitment to abstinence, positive moods, stress, and coping on relapse to cocaine use.","volume":"59","author":"Hall","year":"1991","journal-title":"J Consult Clin Psychol"},{"issue":"5","key":"zoi260336r26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1046\/j.1360-0443.1995.9056072.x","article-title":"The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users.","volume":"90","author":"Gossop","year":"1995","journal-title":"Addiction"},{"issue":"2","key":"zoi260336r27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0005-7916(00)00012-4","article-title":"Psychometric properties of the credibility\/expectancy questionnaire.","volume":"31","author":"Devilly","year":"2000","journal-title":"J Behav Ther Exp Psychiatry"},{"issue":"1","key":"zoi260336r28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1037\/0022-006X.67.1.37","article-title":"The validity of self-reported cocaine use in two groups of cocaine abusers.","volume":"67","author":"Hersh","year":"1999","journal-title":"J Consult Clin Psychol"},{"issue":"2","key":"zoi260336r29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40732-017-0236-1","article-title":"Monitoring cocaine use and abstinence among cocaine users for contingency management interventions.","volume":"67","author":"Holtyn","year":"2017","journal-title":"Psychol Rec"},{"key":"zoi260336r30","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"zoi260336r31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1037\/0022-006X.68.3.515","article-title":"Brief coping skills treatment for cocaine abuse: 12-month substance use outcomes.","volume":"68","author":"Rohsenow","year":"2000","journal-title":"J Consult Clin Psychol"},{"issue":"7","key":"zoi260336r32","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1360-0443.2004.00743.x","article-title":"Motivational enhancement and coping skills training for cocaine abusers: effects on substance use outcomes.","volume":"99","author":"Rohsenow","year":"2004","journal-title":"Addiction"},{"key":"zoi260336r33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/CLEP.S161508","article-title":"Imbalance p values for baseline covariates in randomized controlled trials: a last resort for the use of p values? A pro and contra debate.","volume":"10","author":"Stang","year":"2018","journal-title":"Clin Epidemiol"},{"issue":"1","key":"zoi260336r34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons.","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"issue":"7139","key":"zoi260336r35","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","article-title":"What\u2019s wrong with Bonferroni adjustments.","volume":"316","author":"Perneger","year":"1998","journal-title":"BMJ"},{"issue":"3","key":"zoi260336r36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/10543401003777995","article-title":"MMRM versus MI in dealing with missing data\u2013a comparison based on 25 NDA data sets.","volume":"21","author":"Siddiqui","year":"2011","journal-title":"J Biopharm Stat"},{"issue":"16","key":"zoi260336r37","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.1047","article-title":"A solution to the problem of separation in logistic regression.","volume":"21","author":"Heinze","year":"2002","journal-title":"Stat Med"},{"issue":"5","key":"zoi260336r38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s44220-025-00417-3","article-title":"A systematic review of income and education reporting in psychedelic clinical trials.","volume":"3","author":"Grossman","year":"2025","journal-title":"Nat Ment Health"},{"key":"zoi260336r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109127","article-title":"Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations.","volume":"214","author":"Ortiz","year":"2022","journal-title":"Neuropharmacology"},{"issue":"9","key":"zoi260336r40","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials.","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"zoi260336r41","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1017\/S0033291723003653","article-title":"Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.","volume":"54","author":"Szigeti","year":"2024","journal-title":"Psychol Med"},{"issue":"5","key":"zoi260336r42","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamapsychiatry.2025.0085","article-title":"Expectancy effects, failure of blinding integrity, and placebo response in trials of treatments for psychiatric disorders: a narrative review.","volume":"82","author":"Huneke","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"zoi260336r43","author":"Nayak","year":"2023","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"zoi260336r44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.24119","article-title":"Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression.","volume":"8","author":"Hieronymus","year":"2025","journal-title":"JAMA Netw Open"},{"key":"zoi260336r45","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078607","article-title":"Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.","volume":"386","author":"Hsu","year":"2024","journal-title":"BMJ"},{"key":"zoi260336r46","doi-asserted-by":"publisher","first-page":"l6802","DOI":"10.1136\/bmj.l6802","article-title":"Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study.","volume":"368","author":"Moustgaard","year":"2020","journal-title":"BMJ"},{"key":"zoi260336r47","doi-asserted-by":"publisher","journal-title":"Sci Rep","DOI":"10.1038\/s41598-025-14895-z"},{"key":"zoi260336r48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12991-015-0063-1","article-title":"A systematic appraisal of allegiance effect in randomized controlled trials of psychotherapy.","volume":"14","author":"Dragioti","year":"2015","journal-title":"Ann Gen Psychiatry"},{"issue":"9","key":"zoi260336r49","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/add.16200","article-title":"Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis.","volume":"118","author":"Bharat","year":"2023","journal-title":"Addiction"},{"issue":"7","key":"zoi260336r50","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/add.13327","article-title":"Assessing sample representativeness in randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network.","volume":"111","author":"Susukida","year":"2016","journal-title":"Addiction"},{"key":"zoi260336r1","unstructured":"United Nations Office on Drugs and Crime. World Drug Report 2025. United Nations publication, 2025. Accessed March 26, 2026. https:\/\/www.unodc.org\/unodc\/data-and-analysis\/world-drug-report-2025.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2848757\/hendricks_2026_oi_260336_1777584082.75755.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:30:24Z","timestamp":1778167824000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2848757"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.11029","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]}}}